Latest Health News

Lumos Diagnostics has increased live FebriDx sites to 215 and moved two additional top 100 US urgent care groups into network rollout across more than 40 sites. Two further health-system-owned groups are validating the test across more than 45 sites, but the announcement does not disclose contract values or guaranteed purchase volumes.

CurveBeam AI has secured FDA 510(k) clearance for CT-based bone mineral density measurement, establishing the first regulatory step towards a potential new SaaS offering. The more commercially significant HiRise weight-bearing application still requires a separate clearance.

PGG Wrightson delivered a sharp improvement in FY26 earnings, with Operating EBITDA up 15% to NZ$64.3 million and net profit rising 46% to NZ$15.6 million. The result supports a fully imputed 5.5 cents per share final dividend, although debt and GO-STOCK receivables have also expanded.

Tivan has secured a 50 km² exploration concession immediately north of its Turiscai project in Timor-Leste, subject to formal regulatory grant. The addition would lift the project to eight licences covering approximately 394 km² ahead of planned maiden drilling in the fourth quarter.

PT ANTAM (Persero) Tbk (ASX:ATM) reported Rp6.91 trillion in net profit and Rp62.71 trillion in first-half 2026 sales, with gold contributing the bulk of disclosed revenue. The Indonesian miner is also advancing downstream projects across gold, nickel and bauxite, although project costs and completion dates remain undisclosed.

Kingfish’s adjusted NAV rose 1.2% in August, broadly matching the NZX benchmark as Vista, Fisher & Paykel Healthcare and Delegat delivered the strongest portfolio gains. The fund still trades at a 7.5% discount to NAV, while its one-year shareholder return remains negative.

WasteCo is asking eligible New Zealand shareholders for up to NZ$750,000 in fresh equity as it tackles NZ$40.1 million of debt, a FY2026 loss and an aggressive operational reset. The non-underwritten plan follows a separate placement and is priced at NZ$0.007 per share.

A multimillion-dollar, multiyear NIH grant will fund an expanded access program for Neurizon’s investigational NUZ-001, potentially giving up to 200 US patients access to the therapy for as long as 96 weeks. The program is designed to add long-term safety, survival and biomarker data alongside the pivotal HEALEY ALS trial.

Elixinol Wellness has finalized the divestment of its US operations to Ananda Health, securing upfront and deferred payments totaling approximately A$465,000. This move refocuses the company on its Australian health and wellness portfolio while reducing exposure to US regulatory risks.

CONNEQT Health has inked a marketing deal with US longevity platform Blueprint to boost consumer sales of its FDA-cleared Pulse arterial health monitor, targeting health-conscious Americans focused on preventative care.

Neurizon has appointed Dr Chris Bremer as chief executive as its NUZ-001 ALS program moves towards topline Phase 2/3 results expected in late Q2 2027. The incoming CEO brings more than 20 years of pharmaceutical and biotechnology experience, including over US$1 billion in licensing transactions.

Thrive Tribe Technologies (ASX:1TT) has landed a three-year exclusive distribution agreement with Canadian NATO-registered defence contractor Effective Acceleration Ventures (EAV) to roll out its WooBoard and REFFIND platforms across NATO military forces.